clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association2020Vol. 18pp. -
169
ps2020clinicaldevelopment
Abstract
We used data from a trial of patients with UC to develop a scoring system, called the CDST, which identified patients most likely to enter corticosteroid-free remission during vedolizumab therapy, but not anti-TNF therapy. We validated the vedolizumab CDST in a separate cohort of patients in clinica …